Non-steroidal anti-inflammatory drugs (NSAIDs) are used widely to relieve pain, with or without
|
|
- Rodney Walters
- 6 years ago
- Views:
Transcription
1 May 2013 Contents About NSAIDs What about COXselectivity? How effective are NSAIDs? Adverse effects of NSAIDs How frequent are the adverse effects of NSAIDs? General prescribing guidelines for NSAIDs What to tell the client Conclusion Non-steroidal anti-inflammatory drugs (NSAIDs) are used widely to relieve pain, with or without inflammation, in dogs with acute and chronic musculoskeletal problems. In the UK, ten NSAIDs (in over 30 different brands) are available for use in dogs with acute or chronic musculoskeletal pain. They are carprofen, cinchophen (in combination with prednisolone), cimicoxib, firocoxib, ketoprofen, mavacoxib, meloxicam, phenylbutazone, robenacoxib and tolfenamic acid. Most are available as tablets or oral suspension; a few are available as injections and one as an oral spray. Subscribe to Veterinary Prescriber
2 About NSAIDs All NSAIDs inhibit the enzyme cyclo-oxygenase (COX). Cells use COX in the synthesis of prostaglandins, some of which have physiological functions and some of which are synthesised in conditions where they contribute to pain and inflammation. After absorption, NSAIDs circulate bound to plasma proteins. Most NSAIDs are metabolised in the liver, and the metabolites are excreted in varying proportions in the urine, bile and faeces. What about COX-selectivity? COX exists in at least two isoforms: COX-1 and COX-2. COX-1 is generally considered to be the enzyme associated with normal body functions (e.g. involved in producing prostaglandins in the gastrointestinal tract and the kidneys), while COX-2 is induced in the presence of inflammation. Consequently, the analgesic and anti-inflammatory actions of NSAIDs are believed to depend mainly on their inhibition of COX-2, and the well-known unwanted gastrointestinal effects of NSAIDs on their inhibition of COX-1. It follows, in theory, that a drug that inhibits COX-2 at a lower concentration than is needed to inhibit COX-1 might be safer, and NSAIDs that are more selective for COX-2 have been developed with the aim of minimising gastrointestinal toxicity. However, the concept of COX-1 as good and COX-2 as bad is an oversimplification. 1 Also, COX-selectivity information on specific NSAIDs has limitations: selectivity can depend on the dose of the drug and the animal species, and different methods for testing and calculating selectivity can give inconsistent values for any given NSAID. 2 Evidence on the relative efficacy and safety of NSAIDs therefore needs to come from clinical trials. 1. Innes J et al. Use of nonsteroidal anti-inflammatory drugs for the treatment of canine osteoarthritis. In Practice 2010; 32: KuKanich et al. Clinical pharmacology of nonsteroidal anti-inflammatory drugs in dogs. Vet Anaesth Analg 2012; 39:
3 How effective are NSAIDs? The authors of a systematic review aimed to assess the efficacy of long-term NSAID therapy (at least 28 days) in dogs. 3 They included 15 published trials (8 randomised controlled trials and 7 non-randomised controlled trials; involving a total of 1,595 dogs) but were unable to estimate the efficacy of long-term NSAID therapy, because of a lack of data. However, in one short-term trial (lasting 14 days) it was possible to calculate that 5 dogs (95% confidence interval 2 7) would need to be treated with carprofen (the number needed to treat [NNT]*) instead of placebo to see a positive response on force-plate evaluation in one dog. It is widely believed that there are inter-individual differences in how dogs respond to NSAIDs and it may be worth trying a different NSAID if one is not effective. *Numbers needed to treat (NNTs) (the inverse of the absolute risk difference) are considered to offer a clinically useful measure of the relative benefit of an active treatment over a control. In human medicine, NNTs for effective treatments are usually expected to be in the range of Innes JF et al. Review of the safety and efficacy of long-term NSAID use in the treatment of canine osteoarthritis. Vet Record 2010; 20: Aragon CL et al. Systematic review of clinical trials of treatments for osteoarthritis in dogs. JAVMA 2007; 230: Sanderson RO et al. Systematic review of the management of canine osteoarthritis. Vet Rec 2009; 164: It is unclear from published trials whether any one NSAID is more effective than any other in relieving pain. 3 5 Carprofen, firoxocib and meloxicam are the NSAIDs for which there is the most high-quality published evidence on their use in the treatment of osteoarthritis in dogs. 3 5
4 Adverse effects of NSAIDs Prostaglandins have a physiological role in protecting the gastric mucosa and they also play a significant role in maintaining renal function. Inhibition of prostaglandin synthesis by NSAIDs can therefore result in adverse gastrointestinal and renal effects. The summaries of product characteristics (SPCs) for NSAIDs contraindicate use of the drugs in animals with pre-existing gastrointestinal damage (such as those with ulceration) and in animals with haemorrhagic disorders or blood dyscrasias. The SPCs for most NSAIDs also contraindicate their use in animals with impaired cardiac, hepatic or renal function; in contrast, the SPCs for cimicoxib and firocoxib advise that there may be additional risk in animals with suspected or confirmed cardiac, hepatic or renal function and recommend careful monitoring if used. The authors of a recent systematic review set out to learn more about the adverse effects of NSAIDs in dogs. 6 They searched for all prospective trials in English that assessed the safety of acute or chronic administration of NSAIDs in dogs and found 64 studies, evaluating 14 different NSAIDS (in a total of 3,456 dogs). The strength of evidence was highly variable for the different drugs. For carprofen, firocoxib and meloxicam, there was a high strength of evidence (defined as relevant studies of high quality, including sufficient animals and giving results relevant to the target population); for ketoprofen and robenacoxib, there was a moderate level of evidence (relevant studies of high-to-moderate quality, including sufficient animals and giving results that could be extrapolated to the target population with some confidence); and for rofecoxib and tolfenamic acid, there was an extremely low level of evidence (few high quality studies involving few animals). 6. Monteiro-Steagall BP et al. Systematic review of nonsteroidal antiinflammatory drug-induced adverse effects in dogs. J Vet Intern Med 2013; 27:
5 How frequent are the adverse effects of NSAIDs? The most common outwardly detectable effects reported The review s authors also looked at the trial results on in the clinical trials in the systematic review were: vomiting, diarrhoea, anorexia, lethargy and melaena. 6 Also re- liver enzyme activity during or after long-term (at least 28 pathology monitoring. There were no significant changes in ported were: faecal blood, bleeding, colitis, abdominal pain, days) administration of NSAIDs. There were no differences aggressiveness or behaviour change, hypersalivation, polydipsia, polyuria, adipsia, constipation, icterus, skin reactions ous NSAIDs or between treated and control groups. Renal in the incidence of renal adverse effects between the vari- and weight loss. Out of all the studies, two gastrointestinal function tests failed to detect renal adverse effects in dogs perforations were recorded: one in a dog that accidentally undergoing general anaesthesia and submitted to hypovolaemic and/or hypotensive stress. Outwardly detectable received a double dose of firocoxib; the other in a dog that received an NSAID concurrently with a topical corticosteroid. When NSAIDs were compared with placebo effects were seen in 4 studies and included polyuria, poly- adverse effects that could have been attributable to renal (in a subgroup of 25 randomised blinded trials), there was dipsia and adipsia although it cannot be certain that these a statistically significant difference between NSAID and were due to NSAID use. They comment that adverse effects placebo groups (in 5 out of the 25 trials) for the following on the liver associated with NSAID use appear more likely objective outcome measures: scores for gastrointestinal to be idiosyncratic, in contrast to kidney injury and gastrointestinal effects, which can be dose-dependent. lesions (which were higher with NSAIDs), and platelet aggregation, food consumption and body weight (which were A problem with this evidence is that most of the trials all reduced compared with placebo). (55%) were in research dogs, which are usually young and free of naturally-occurring disease; only 45% of the studies It was not possible from the data provided in the trials to were clinical (i.e. involved dogs likely to be representative of estimate the true incidence of any of the adverse effects in dogs treated in practice). The results therefore have limited dogs. relevance to the use of NSAIDs in practice. 6. Monteiro-Steagall BP et al. Systematic review of nonsteroidal antiinflammatory drug-induced adverse effects in dogs. J Vet Intern Med 2013; 27:
6 General prescribing guidelines for NSAIDs The potential benefits of treatment with an NSAID must be weighed against the risks. An NSAID should be used in the lowest effective dose, without prescribing more than the maximum recommended dose. Most NSAIDs are recommended for once daily administration daily; some are given twice daily, or on alternate days (check the product SPC for dosage and administration information). An exception is mavacoxib, which, because of its long half life (around days) is given once a month. If one NSAID is ineffective, a different one may be considered; it is logical for a vet to acquire experience with a few from the many NSAIDs available. The risk of renal adverse effects might be increased if NSAIDs are used concurrently with other drugs that affect renal function (e.g. aminoglycosides, diuretics). Renal function should be monitored in dogs with pre-existing renal disease. Some products SPCs advise against use in dogs with renal dysfunction. Using a high dose of NSAID, or using an NSAID concurrently with a corticosteroid, or using two NSAIDs together appear more likely to cause adverse gastrointestinal effects. 2 The risk of adverse effects can be reduced by checking the animal s record for co-existing disease (e.g. renal dysfunction) and current drug treatments (particularly corticosteroids) before prescribing. 7. Lascelles BD et al. Gastrointestinal tract perforation in dogs treated with a selective cyclooxygenase-2 inhibitor: 29 cases ( ). Vet Med Assoc 2005; 227: KuKanich et al. Clinical pharmacology of nonsteroidal anti-inflammatory drugs in dogs. Vet Anaesth Analg 2012; 39: When switching a patient from one NSAID to another (when no adverse effects have been seen), some guidelines recommend a washout period of 5 to 7 days to reduce the likelihood of drug interactions. 2 ) However, there seems to be no rational basis for this and for most NSAIDs the replacement NSAID could be started 24 hours after stopping the previous one. An exception is mavacoxib (which has a very long half life) for which the SPC recommends waiting 1 month before starting another NSAID. Clinical signs that suggest ulceration include depression, anorexia, reduced appetite, vomiting, diarrhoea and hematochezia or melaena. But ulceration can occur without overt clinical signs and, conversely, symptoms such as vomiting, anorexia and diarrhoea can occur independently of gastrointestinal damage or ulceration. 2
7 What to tell the client Informing clients of the potential adverse effects of NSAID therapy and signs of toxicity is likely to promote safer use of this class of drugs. Typical adverse effects of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy generally occur within the first 2 weeks of therapy to ensure the dog has easy access to plenty of water at all times; and are in most cases transient and disappear after stopping the treatment. Advise on the need for re-examination and/or regular laboratory tests where appropriate. Clients should be also advised: not to increase the dose if the dog seems to be in greater pain (e.g. after a long walk); to stop administering the drug and contact the vet if the dog becomes unwell (e.g. with vomiting or diarrhoea); to know the dosage frequency; not to give human NSAIDs to dogs; to keep the medicine out of the reach of animals; flavoured tablets if found and eaten in bulk by the animal could lead to toxicity.
8 Conclusion Overall, published clinical trial evidence does not show any one NSAID to be more effective or safer than any other in the management of musculoskeletal problems. Carprofen, firoxocib and meloxicam are the NSAIDs with the best published evidence on efficacy and safety (i.e. the ones about which there can be greater certainty of their effects). The safety of NSAIDs has been poorly studied and the true incidence of adverse effects from NSAIDs in dogs is not known. Contact Veterinary Prescriber to give feedback on this article or get involved as a writer, commentator or editorial consultant. Use the mail link below to get in touch. Subscribe to Veterinary Prescriber Veterinary Prescriber is an essential resource for veterinary professionals who want impartial, evaluated and practical information on veterinary medicines. The succinct articles are clearly referenced, make a distinction between evidence and opinion, and are easy to read on computer, tablet or smartphone. The practical what to say to clients advice in the articles, and unique product guides, help you to give better advice to clients. We aim to make the information easy-to-read and convenient. Use the contents list on the first page to get to the parts of the article you want to read; use the forward and back arrows to move from page to page; and click the Veterinary Prescriber logo in the top left hand corner to get back to the first page. We d like to hear from you Click the Veterinary Prescriber logo below to go to the website and fill in the contact form: to find out about how to subscribe to Veterinary Prescriber, to send us feedback on the articles and/ or the website, to suggest topics for articles, or to tell us if you would like to write or comment on articles. And don t forget to follow on Facebook and Twitter for the latest updates in independent veterinary medicines information. copyright 2013 Mixolydian Publications ltd. All rights reserved.
Metacam 1.5 mg/ml oral suspension for dogs
Metacam 1.5 mg/ml oral suspension for dogs Species:Dogs Therapeutic indication:pharmaceuticals: Neurological preparations: Analgesics, Other NSAIDs, Locomotor (including navicular and osteoarthritis) Active
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rycarfa 100 mg tablets for dogs (BE, DE, ES, FR, IE, IT, NL, PT, UK) Rycarfa vet 100 mg tablets for dogs (DK, FI) Carprox
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Animeloxan 1.5 mg/ml oral suspension for dogs. Active substance: Meloxicam 1.5 mg (equivalent to 0.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Animeloxan 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of suspension contains:
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 5 mg/ml solution for injection for cattle, pigs, dogs and cats. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Carprodyl Quadri 120 mg chewable tablets for dogs Carprodyl vet. 120 mg chewable tablets for dogs (FI, SE, DK) 2. QUALITATIVE
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationWhat Veterinarians Should Tell Clients About Pain Control and Their Pets
What Veterinarians Should Tell Clients About Pain Control and Their Pets by Michele Sharkey, DVM, MS, Office of New Animal Drug Evaluation; Margarita Brown, DVM MS, Office of Surveillance and Compliance;
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates
More informationNon-steroidal anti-inflammatory drugs in dogs and cats what s new?
continuing education Nonsteroidal antiinflammatory drugs in dogs and cats what s new? Isabelle Iff Dr.med.vet. DipECVAA CertVetAc (IVAS) Veterinary Anaesthesia Services Zürcherstrasse 39 CH 8400 Winterthur
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 20 mg/ml solution for injection for cattle, pigs and horses. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationMeloxicam vs etodolac cox 2 inhibition
Meloxicam vs etodolac cox 2 inhibition The Borg System is 100 % Meloxicam vs etodolac cox 2 inhibition of GI. Aspirin inhibits plt aggregration via inhibition of platelet COX. Meloxicam least. Etodolac
More informationMetacam is an anti-inflammatory medicine used in cattle, pigs, horses, dogs, cats and guinea pigs.
EMA/CVMP/259397/2006 EMEA/V/C/000033 An overview of Metacam and why it is authorised in the EU What is Metacam and what is it used for? Metacam is an anti-inflammatory medicine used in cattle, pigs, horses,
More informationCaution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
BOEHRINGER INGELHEIM VETMEDICA, INC. USA Product Label http://www.vetdepot.com 2621 NORTH BELT HIGHWAY, ST. JOSEPH, MO, 64506 2002 Telephone: 800 325 9167 Fax: 816 236 2717 Email: www.bi vetmedica.com
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/33
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/33 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Acticam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of Acticam 1.5
More informationVeterinary Medicinal Product
Veterinary Medicinal Product Carprodyl Quadri 120 mg chewable tablets for dogs PART I B Pharmaceutical Form Chewable tablet Veterinary Medicinal Product Carprodyl Quadri 120mg chewable tablets for dogs
More informationNSAID Toxicity in Dogs & Cats Beware of Ibuprofen!
NSAID Toxicity in Dogs & Cats Beware of Ibuprofen! One of the most common drug toxicities in companion animal medicine is accidental ingestion of over-the-counter non-steroid anti-inflammatory (NSAID)
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metacam 5 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationNSAIDs: the Past, Present, and Future
NSAIDs: the Past, Present, and Future Resident Seminar - November 2017 Lisanne Gallant, DVM Large Animal Medicine Resident Outline Physiology Review Use in Large Animals Adverse Effects Cases The Future
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Loxicom 0.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metacam 5 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Rifen 100 mg/ml solution for injection for horses, cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/127
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/127 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metacam 5 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NEFOTEK 100 mg/ml solution for injection for cattle, horses and pigs [AT, CZ, IE, PL, SK, UK, DE, FR, ES, HU, IT, SI] COXOFEN
More informationJust where it s needed.
Relief. Just where it s needed. Tissue-selective 7,8 Strong safety profile 5,6,10,11 For dogs and cats Onsior is available in a range of convenient and easy-to-dose formulations. Injectable solution for
More informationNSAIDs Are You Following the Rules?
NSAIDs Are You Following the Rules? As equestrians, we expect a lot from our performance horses. Sometimes pain and inflammation of their joints can happen right before a show or competition. Before administering
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rheumocam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active
More informationPART 1 B1 SUMMARY OF PRODUCT CHARACTERISTICS (SPC)
PART 1 B1 SUMMARY OF PRODUCT CHARACTERISTICS (SPC) SPC for Acticam 1 mg Chewable Tablets for dogs and Acticam 2.5mg Chewable Tablets for dogs are presented in subsequent pages, SPC for Acticam 1 mg Chewable
More informationOptimizing Pain Control A Critical Understanding of NSAIDs
Optimizing Pain Control A Critical Understanding of NSAIDs James S. Gaynor, DVM, MS, DACVA, DAAPM Colorado Springs, CO USA 719-266-6400 800-791-2578 www.peakvets.com Principles of Acute & Chronic Pain
More information[09/2018] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
[09/2018] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cronyxin 50 mg/g Oral paste for horses (DE, AT, BE, EE, LV, LT, ES, FR, IE, IT, NL, PL, UK) Cronyxin vet
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AT, BE, BG, CY, CZ, DE, EE, EL, ES, FR, HR, HU, IE, IT, LT, LU, NL, PT, RO, SK, UK: Kelaprofen 100 mg/ml, solution for injection
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Onsior 6 mg tablets for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rheumocam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active
More informationPrescription Label. Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long):
Prescription Label Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long): Prescribing Veterinarian's Name & Contact Information: Refills: [Content to be provided
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Inflacam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Novem 5 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Meloxidyl 1.5 mg/ml oral suspension for dogs. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Composition for 1 ml Active
More informationEPAR type II variation for Metacam
23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Meloxidyl 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Composition for 1 ml Active
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Inflacam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active
More informationMetacam. The Only NSAID Approved for Cats in the US. John G. Pantalo, VMD Professional Services Veterinarian. Think easy. Think cat. Think METACAM.
Metacam The Only NSAID Approved for Cats in the US John G. Pantalo, VMD Professional Services Veterinarian Think easy. Think cat. Think METACAM. Today s Agenda New pain management guidelines for cats Only
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT EQUIOXX 8.2 mg/g oral paste for horses. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each syringe contains 7.32 g
More informationStart of new generation of NSAIDs?
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Start of new generation of NSAIDs? Author : Peter Lees Categories : Vets Date : May 16, 2011 Peter Lees discusses development
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT
SUMMARY OF PRODUCT CHARACTERISTICS Revised: December 2013 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Flunixin 50 mg/ml Solution for Injection for Cattle, Horses and Pigs (United Kingdom, Germany, Iceland)
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT GALLIPRANT 20 mg tablets for dogs GALLIPRANT 60 mg tablets for dogs GALLIPRANT 100 mg tablets for dogs 2. QUALITATIVE
More informationThe new meloxicam range for cattle, pigs & horses
The new meloxicam range for cattle, pigs & horses Melovem 5 mg/ml Melovem 20 mg/ml Melovem 30 mg/ml The new Melovem range + Many indications for cattle, horses and pigs + Accurate dosing Dopharma has obtained
More informationApproved for Orthopedic and Soft-tissue Surgery
Approved for Orthopedic and Soft-tissue Surgery tlr8.5x11_rsg2 3/17/1 11:36 AM Page 4 Designed for Dogs bout NSAIDs Facts about NSAIDs f NSAIDs is to relieve the pain and ssociated with surgery with a
More informationFaculty of Veterinary Science, Szent Istvan University Department of Pharmacology and Toxicology. Nora Line
Faculty of Veterinary Science, Szent Istvan University Department of Pharmacology and Toxicology Meloxicam usage in cats, and its potential adverse effects on the renal function Nora Line Tutor: György
More informationSUMMARY OF PRODUCT CHARACTERISTICS. KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats 2. QUALITATIVE
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT DINALGEN 60 mg/ml solution for injection for pigs (all countries except FI and SE) DINALGEN VET 60 mg/ml solution for injection
More informationSea Turtle Analgesics Selection - NSAIDS. Loggerhead Coquina (postoperative ketorolac)
Sea Turtle Analgesics Selection - NSAIDS Craig A. Harms, D.V.M., Ph.D, Dipl. ACZM North Carolina State University Loggerhead Coquina (postoperative ketorolac) $& Sources of Information!! Anecdote!! Expert
More informationScientific discussion
21 February 2011 EMA/CVMP/510016/2010 Veterinary Medicines and Product Data Management This module reflects the initial scientific discussion for the approval of Melosus (as published in February 2011).
More informationWithdrawal period: 93 days Milk: Not authorised for use in animals producing milk for human consumption.
A. LABELLING PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE CARTON BOX AND LABELS OF 100 ml and 250 ml 1. NAME OF THE VETERINARY MEDICINAL PRODUCT TILKOMAY 300 mg/ml + 90 mg/ml solution
More informationN.C. A and T List of Approved Analgesics 1 of 5
1 of 5 Note to user: This list of commonly used analgesics and sedatives is not all-inclusive. The absence of an agent does not necessarily mean it is unacceptable. For any questions, call the Clinical
More informationCommonly Used Analgesics
Commonly Used Analgesics The following analgesics are intended for general use in the species of laboratory animals commonly used at NEOUCOM. The animals genetic background and other factors may have a
More informationMeloxicam withdrawal time veterinarian bovine
Meloxicam withdrawal time veterinarian bovine The Borg System is 100 % Meloxicam withdrawal time veterinarian bovine Meloxicam Pain Relief in Cows and Calves. Meloxicam meat and milk withdrawal the standard
More informationIs Robenacoxib Superior to Meloxicam in Improving Patient Comfort in Dog Diagnosed With a Degenerative Joint Process?
Is Robenacoxib Superior to Meloxicam in Improving Patient Comfort in Dog Diagnosed With a Degenerative Joint Process? A Knowledge Summary by Adam Swallow BVSc MRCVS 1* 1 University of Bristol * Corresponding
More informationAustralian and New Zealand College of Veterinary Scientists. Membership Examination June Veterinary Pharmacology Paper 1
Australian and New Zealand College of Veterinary Scientists Membership Examination June 2012 Veterinary Pharmacology Paper 1 Perusal time: Fifteen (15) minutes Time allowed: Two (2) hours after perusal
More informationCritical appraisal Randomised controlled trial questions
Critical appraisal Randomised controlled trial questions Moreau et al. (2003) Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis Introduction
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Ketink 100 mg/ml solution for injection for cattle, horses and pigs [Austria, Bulgaria, Cyprus, Czech Republic, Estonia, France,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Zubrin EN 1/42
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Zubrin EN 1/42 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 30 mg oral lyophilisates for dogs Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active
More informationIrish Medicines Board
IRISH MEDICINES BOARD ACT 1995 EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS 2007 (S.I. No. 786 of 2007) VPA:10778/003/002 Case No: 7003735 The Irish Medicines Board in exercise of the powers
More information- Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
MERIAL LTD. USA Product Label http://www.vetdepot.com 3239 SATELLITE BLVD., DULUTH, GA, 30096 Telephone: 888-637-4251 Website: www.merial.com GASTROGARD Merial (omeprazole) Oral Paste for Equine Ulcers
More informationEar drops suspension. A smooth, uniform, white to off-white viscous suspension.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT OTOMAX EAR DROPS SUSPENSION 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of the veterinary medicinal product contains:
More informationFinal Report. Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014
Final Report Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014 PUBLISHED BY Meat & Livestock Australia Limited Locked Bag 991 NORTH SYDNEY NSW 2059
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Issued March 2017 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Recicort 1.77 mg/ml + 17.7 mg/ml ear drops, solution for dogs and cats Recicort vet 1.77 mg/ml + 17.7 mg/ml
More informationScientific Discussion post-authorisation update for Rheumocam extension X/007
5 May 2011 EMA/170257/2011 Veterinary Medicines and Product Data Management Scientific Discussion post-authorisation update for Rheumocam extension X/007 Scope of extension: addition of 20 mg/ml solution
More informationCarprofen is a white, crystalline compound. It is freely soluble in ethanol, but practically insoluble in water at 25 C.
USA Product Label http://www.vetdepot.com PFIZER INC. PFIZER ANIMAL HEALTH 235 E. 42ND ST., NEW YORK, NY, 10017 Telephone: 269-833-4000 Customer Service: 800-733-5500 and 800-793-0596 Veterinary Medical
More informationIndicated for the treatment of pruritus associated with allergic dermatitis and the clinical manifestations of atopic dermatitis in dogs.
Zoetis UK Limited Telephone: 0845 300 8034 Website: www.zoetis.co.uk Email: customersupportuk@zoetis.com Apoquel film-coated for dogs Species: Therapeutic indication: Active ingredient: Product: Product
More informationOnly for Intravenous Use in Beef and Dairy Cattle. Not for Use in Dry Dairy Cows and Veal Calves. For Intravenous or Intramuscular Use in Horses.
INTERVET INC., MERCK ANIMAL HEALTH USA Product Label http://www.vetdepot.com 556 MORRIS AVE., SUMMIT, NJ, 07901 Telephone: 862-245-4321 Order Desk: 800-648-2118 Fax: 862-245-4935 Customer Service: 800-521-5767
More informationSearch Search pages & people Search. Search Search pages & people. Search. Cipla 159 for pain
Search Search pages & people Search Search Search pages & people Search Cipla 159 for pain Pill with imprint CIPLA 159 is Yellow, Round and has been identified as Meloxicam 15 mg. It is supplied by Cipla
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Trocoxil 6 mg chewable tablets for dogs Trocoxil 20 mg chewable tablets for dogs Trocoxil 30 mg chewable tablets
More informationSOP #: Page: 1 of 6 Rodent Analgesia
Comparative Medicine Page: 1 of 6 Rodent Analgesia The intent of this Standard Operating Procedure (SOP) is to describe commonly used analgesics provided to rodents housed at Comparative Medicine (CM).
More informationUnshakeable confidence
NEW PRODUCT OF THE YEAR as voted by vets for the 2nd year running** Unshakeable confidence Osurnia is the only otitis externa* treatment that applies like a liquid and stays like a gel. Right where you
More informationPATIENT INFORMATION LEAFLET DYNA CEFPODOXIME 100 mg / DYNA CEFPODOXIME SUSPENSION:
SCHEDULING STATUS S4 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: DYNA CEFPODOXIME 100 mg (film coated tablet) DYNA CEFPODOXIME SUSPENSION (powder for oral suspension) Please read this leaflet carefully
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationEquine gastric squamous and glandular disease update
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Equine gastric squamous and glandular disease update Author : Gayle Hallowell Categories : Equine, Vets Date : July 3, 2017
More informationMobility Issues and Arthritis
Mobility Issues and Arthritis 1. Overview of end stage of the disease. Mobility issues are often attributed to normal aging by pet owners, and can have insidious symptoms as they may progress slowly without
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare 20 mg/ml solution for injection for cattle and pigs (UK, IE, FR) Odimar 20 mg/ml solution for injection for cattle
More informationDon t let arthritis slow down your dog!
Don t let arthritis slow down your dog! abcd DOG CAT ACUTE CHRONIC PERIOPERATIVE INJECTABLE ORAL SUSPENSION CHEWABLE Keeping your dog in the prime of life Is your dog at risk of developing arthritis? As
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Flukiver 5% w/v Oral Suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance Closantel (as Clostanel sodium)
More informationOralject P-BUTAZONE* PASTE ORAL ANTI-INFLAMMATORY ANALGESIC AGENT FOR HORSES
Draft Label: ORALJECT P-BUTAZONE * PASTE Page 1 of 13 (AUS/NZ) 30 ml syringe label Date Drafted : MAIN PANEL PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY Oralject
More informationB. PACKAGE LEAFLET 1
B. PACKAGE LEAFLET 1 PACKAGE LEAFLET NICILAN 400 mg/100 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
More informationRestore life and vitality in your dog. Feel the same results as an owner.
Restore life and vitality in your dog. Feel the same results as an owner. Your dog, Cushing s syndrome and you This booklet has been designed to help answer questions that you may have about Cushing s
More informationPrescription Label. Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long):
Prescription Label Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long): Prescribing Veterinarian's Name & Contact Information: Refills: [Content to be provided
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metrobactin 500 mg tablets for dogs and cats (AT, BE, BG, CY, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PL, PT, RO, SI,
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Active substance: cefalexin (as cefalexin monohydrate) mg
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cefaseptin 750 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: Active substance: cefalexin
More informationCopper-Storage Liver Disease Basics
Copper-Storage Liver Disease Basics OVERVIEW Abnormal accumulation of copper in the liver, causing sudden (acute) inflammation of the liver (hepatitis) or long-term (chronic) hepatitis and eventually progressive
More informationCAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
VÉTOQUINOL USA, INC. USA Product Label http://www.vetdepot.com 4250 N. SYLVANIA AVENUE, FORT WORTH, TX, 76137 Customer Service: 800 267 5707 Website: Email: www.vetoquinolusa.com info@vetoquinolusa.com
More informationRestore life and vitality in your dog. Feel the same results as an owner.
Restore life and vitality in your dog. Feel the same results as an owner. Your dog, Cushing s syndrome and you This booklet has been designed to help answer questions that you may have about Cushing s
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 18 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cardisure flavoured 10 mg Tablets For dogs (Austria, Belgium, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands,,
More informationINTRODUCTION TO WILDLIFE PHARMACOLOGY. Lisa Fosco Wildlife Rehabilitation Manager Toronto Wildlife Centre
INTRODUCTION TO WILDLIFE PHARMACOLOGY Lisa Fosco Wildlife Rehabilitation Manager Toronto Wildlife Centre General Pharmacology Factors That Affect Drug Absorption The dosage form Blood supply to the area
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products EMEA/MRL/571/99-FINAL February 1999 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS MELOXICAM SUMMARY REPORT (2) 1. Meloxicam (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-
More informationPain Management in Racing Greyhounds
Pain Management in Racing Greyhounds Pain Pain is a syndrome consisting of multiple organ system responses, and if left untreated will contribute to patient morbidity and mortality. Greyhounds incur a
More informationComparison of Robenacoxib and carprofen in palliative management of cancer pain
Comparison of Robenacoxib and carprofen in palliative management of cancer pain Department of Veterinary Medicine of Companion Animals at University Utrecht Research Project of L.M.A. van der Hoeven Supervisor:
More informationLABELLING AND PACKAGE LEAFLET
LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE CARTON BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MILTEFORAN 20 mg/ml oral solution for dogs miltefosine 2.
More informationPOST-OPERATIVE ANALGESIA AND FORMULARIES
POST-OPERATIVE ANALGESIA AND FORMULARIES An integral component of any animal protocol is the prevention or alleviation of pain or distress, such as that associated with surgical and other procedures. Pain
More informationANNEX III AMENDMENTS TO THE SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET
ANNEX III AMENDMENTS TO THE SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET 1 AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE SUMMARY OF PRODUCT CHARACTERISTICS FOR MOXIFLOXACIN CONTAINING
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationIrish Medicines Board
IRISH MEDICINES BOARD ACT 1995, as amended European Communities (Animal Remedies) (No. 2) Regulations 2007 VPA: 10988/081/002 Case No: 7007872 The Irish Medicines Board in exercise of the powers conferred
More information